Invest1 publisher2 min readPublished
Korea's home-built cyclotron cuts zirconium-89 imports to under 5% of supply
Korea Atomic Energy Research Institute's home-built RFT-30 cyclotron has cut Korea's reliance on imported zirconium-89 from 100% to under 5%. The institute also ships the isotope abroad, where its cyclotron research head says U.S. FDA approval could lift demand much further.
The Investor · Invest desk
What happened
- KAERI's Advanced Radiation Technology Institute built the whole zirconium-89 process in-house, from cyclotron irradiation to separation and purification equipment, and localized it in 2018.
- RFT-30 is the first mid-sized cyclotron developed with domestic technology, designed for repeated mass production of isotopes where research reactors such as HANARO are not.
- An automated mass-production line supplies Korean medical institutions and ships zirconium-89 to the United States, China, South Africa and Thailand.
- Park said the institute has also localized raw materials for germanium-68, used to diagnose glioma, and copper-67, a next-generation therapeutic isotope.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- capability Korean medical institutions now draw more than 95% of their zirconium-89 from a domestic line, so a foreign supply outage would touch under 5% of what they use.
- exposure The gallium-68 generator, used on intractable cancers, is still a full import, and Korea depends on foreign suppliers for it until a localization project joining a Ministry of Science and ICT program next year delivers.
- decision Serving the larger foreign demand Park describes would need capacity the institute has not yet committed to, since its 35 MeV cyclotron is still a mid- to long-term plan in preparation.
The export claim rests on a list of four destination countries [7]. The report on the institute's 20th anniversary [13] does not give export volumes, prices, revenue or the cost of running a 30 MeV cyclotron [1]. Until it does, the export half of the story cannot be weighed against anything. The import half has a figure, and that figure comes eight years after the 2018 localization [2].
Park's condition on U.S. approval [8] also says something about who is buying today. The report describes zirconium-89 as an isotope used in antibody and immunology research, with a half-life long enough for effective cancer diagnosis [6]. On that description, the current shipments abroad serve the demand that exists without an FDA approval. The much larger demand Park expects depends on getting one.
If approval arrives, output becomes the limit. The institute's answer is a 35 MeV cyclotron, 5 MeV or about 17% above RFT-30's rating [3], along with AI-based autonomous control and automated production of high-purity isotopes [12]. All of that is described in the future tense, and the bigger machine is still a mid- to long-term plan in preparation [11]. If approval does not come, exports stay a side business next to domestic supply. A third outcome treats zirconium-89 less as a product and more as a method the lab repeats on the imports that remain, and the gallium-68 generator project [10] is the next test of that method.
I think the third outcome is the one the evidence supports best. The measured result is at home, and every item on Park's investment list is process or equipment inside the institute [12]. The counter-case is Park's own. He said the aim is to make the institute an Asian hub for radioisotope development [12], and if foreign demand rises as far as he expects after a U.S. approval [8], exports become the bigger business and the 35 MeV plan becomes a decision about commercial capacity. An FDA approval, or published export volumes approaching domestic use, would make that the better reading.
What to watch
- A U.S. FDA decision on zirconium-89, which Park Jung-hoon says could lift demand from other countries much further.
- Whether KAERI publishes export volumes or revenue for its zirconium-89 shipments to the United States, China, South Africa and Thailand.
- Whether the 35 MeV cyclotron plan gets funding and a timeline, and whether the gallium-68 generator project starts on schedule next year.